Radiotherapy is a well-established treatment for cancer. However, the existence of radioresistant cells is one of the major obstacles in radiotherapy. In order to understand the mechanism of cellular radioresistance and develop more effective radiotherapy, we have established clinically relevant radioresistant (CRR) cell lines, which continue to proliferate under daily exposure to 2 Gray (Gy) of X-rays for >30 days. X-ray irradiation significantly induced autophagic cells in parental cells, which was exiguous in CRR cells, suggesting that autophagic cell death is involved in cellular radiosensitivity. An autophagy inducer, rapamycin sensitized CRR cells to the level of parental cells and suppressed cell growth. An autophagy inhibitor, 3-methyladenine induced radioresistance of parental cells. Furthermore, inhibition of autophagy by knockdown of Beclin-1 made parental cells radioresistant to acute radiation. These suggest that the suppression of autophagic cell death but not apoptosis is mainly involved in cellular radioresistance. Therefore, the enhancement of autophagy may have a considerable impact on the treatment of radioresistant tumor.
Radiotherapy is a well-established treatment for cancer. However, the existence of radioresistant cells is one of the major obstacles in radiotherapy. In order to understand the mechanism of cellular radioresistance and develop more effective radiotherapy, we have established clinically relevant radioresistant (CRR) cell lines, which continue to proliferate under daily exposure to 2 Gray (Gy) of X-rays for >30 days. X-ray irradiation significantly induced autophagic cells in parental cells, which was exiguous in CRR cells, suggesting that autophagic cell death is involved in cellular radiosensitivity. An autophagy inducer, rapamycin sensitized CRR cells to the level of parental cells and suppressed cell growth. An autophagy inhibitor, 3-methyladenine induced radioresistance of parental cells. Furthermore, inhibition of autophagy by knockdown of Beclin-1 made parental cells radioresistant to acute radiation. These suggest that the suppression of autophagic cell death but not apoptosis is mainly involved in cellular radioresistance. Therefore, the enhancement of autophagy may have a considerable impact on the treatment of radioresistant tumor.
Radiotherapy and radiochemotherapy are well-established treatment modalities for various cancers. Tumor cells have the capacity to cope with radiotherapy and chemotherapy through multiple pathways of growth arrest and cell death.[1] Various modes of cell death have been known, such as necrosis, apoptosis, accelerated senescence, mitotic catastrophe and autophagic cell death.[2, 3, 4] Among these, apoptosis has been the most extensively studied and has revealed to be the primary mode of cell death in leukemia and lymphoma cells.[5] However, the concept of cell death is continuously evolving and the role of apoptosis in radiation or anticancer drug treatment is being reappraised.[6] Although death after irradiation in leukemia and lymphoma is preceded by apoptotic changes, apoptosis has little or even no role in the killing of epithelial neoplastic cells by radiation.[7] Moreover, early response of cell death, apoptosis is not necessarily correlated with overall tumor sensitivity to anticancer treatment.[8, 9]Compared with other cell death patterns, autophagy induced by radiation or anticancer drugs is less studied.[4] Dual role of autophagy has been reported, cell death and survival. Therefore, autophagy is considered to be a double-edged sword in the process of tumor development.[10] Autophagy suppresses tumor formation by triggering a non-apoptotic cell death program. The Beclin-1 gene, an ortholog of Apg6, which participates in the induction of autophagy in response to starvation is reported to be one of tumor-suppressor genes.[11] On the contrary, the activation of autophagy may permit cancer cells to survive within the nutrient-poor environment.[12] Anticancer drug-induced autophagy can lead either to cell death or alternatively to protection against cell death. An anticancer drug, tamoxifen induces autophagic cell death in human mammary carcinomaMCF-7 cells.[13] By contrast, in response to sulindac and tumor necrosis factor-α, autophagy is induced as a cell survival mechanism.[14, 15, 16] Autophagy may protect some cancer cells from ionizing radiation possibly by removing damaged macromolecules and organelles such as mitochondria, which could protect against apoptosis and allow continued survival of transformed cells.[17] Ionizing radiation does not induce apoptosis but induces autophagic changes in glioblastoma cell lines irrespective of their relative radiosensitivity.[18] It is suggested that a basal enhanced level of autophagy in cancer cells contributes to therapy resistance but prolonged activation of autophagy may lead to cell death by cellular self-degradation.[19]In order to develop more effective tumor radiotherapy, we have recently established clinically relevant radioresistant (CRR) cell lines, HepG2-8960-R and HepG2-R from HepG2, and SAS-R from SAS, independently.[20, 21] These cells continue to proliferate with daily exposure to 2 Gray (Gy) of X-rays for >30 days, which corresponds to the standard protocol of fractionated radiotherapy for cancer treatment. This study revealed that CRR cells were refractory to the induction of autophagy after irradiation and that facilitation of autophagy by rapamycin (RPM) abrogated the CRR phenotype. We also found that repression of autophagy induced radioresistance in non-CRR parental cells.
Results
Microscopic analysis of radiation-induced cell death after acute exposure to 10 Gy of X-rays
We pursued morphological changes characteristic to radiation-induced cell death. Within 2 days after 10 Gy of acute radiation (AR), prominent changes in morphology were not observed in HepG2 cells other than a slight increase in the cell size (Figures 1a–c). At day 3 after AR, the number of round cells, that is, mitotic cells increased (Figure 1d). Thereafter dead cells became obvious and multinucleated cells, characteristic to mitotic catastrophe, were also observed (Figures 1e and f). Dying cells were classified into two types: apoptotic cells with apoptotic bodies (Figure 1g) and non-apoptotic cells without apoptotic bodies (Figure 1h). The frequency of non-apoptotic cells was significantly higher than that of apoptotic cells.
Figure 1
Microscopic appearance of parental HepG2 cells after exposure to a single dose of 10-Gy X-rays. (a) Mitotic figures but a few were observed in HepG2 cells without irradiation. (b) No remarkable changes but the increase in cell size were observed 1 day after exposure. (c) The increase in cell size was obvious 2 days after exposure. (d) Mitotic figures were apparent 3 days after exposure (black arrows). (e) At day 5 after exposure, a frequent number of dying cells were seen (black arrow heads). Multinucleated cells showing mitotic catastrophe were also increased (white arrows). (f) At day 7 after exposure. (g) Dead cells with apoptotic bodies (arrow heads; 5 days after exposure to X-rays). (h) Dead cell without apoptotic bodies (arrow head; 5 days after exposure to X-rays)
Basal levels of dead cells were higher in radioresistant HepG2-8960-R than HepG2 (Figure 2a), presumably due to maintenance irradiation at 2 Gy per day. During this experimental period, distinguishable induction of cell death was not observed (Figures 2a–f). At day 3 after AR, inconsiderable increase in non-apoptotic cell death was observed in HepG2-8960-R (Figure 2d). After that no increase in either dead cells or mitotic catastrophe was observed (Figures 2e and f). These suggested that apoptosis is not a major type of cell death induced by ionizing radiation.
Figure 2
Microscopic appearance of radioresistant HepG2-8960-R cells after acute exposure to 10 Gy of X-rays. (a) HepG2-8960-R cells 2 days after exposure to 2 Gy of X-rays (maintenance irradiation). Mitotic cells (black arrows), dead cells (black arrow heads) and multinucleated cells showing mitotic catastrophe (white arrows) were observed. (b) No remarkable changes were observed 1 day after exposure to 10 Gy of X-rays. (c) Unlike HepG2 cells the increase in cell size was not obvious 2 days after exposure to 10 Gy of X-rays. (d) Mitotic figures were not apparent compared with HepG2 cells 3 days after exposure to 10 Gy of X-rays. (e) At day 5 after exposure to 10 Gy of X-rays, the frequency of dead cells was lower compared with HepG2. (f) At day 7 after exposure to 10 Gy of X-rays, the number of cells in mitotic catastrophe was not increased
To examine to what extent X-ray exposure induces apoptotic changes, apoptotic cell death was evaluated by different methods. Basal level of annexin V-positive apoptotic cells observed under a microscope was significantly higher in HepG2-8960-R than in HepG2 (Figure 3a). AR of 10 Gy increased the frequency of annexin V-positive cells both in HepG2 and HepG2-8960-R. The increase was faster and higher in HepG2-8960-R than that in HepG2. The maximum level was about 20% in HepG2-8960-R and 10% in HepG2. The frequency of annexin V-positive cells was constant in both cell lines after reaching the maximal level. On the other hand, fractionated radiation (FR) of 2 Gy per day did not induce significant frequency of annexin V-positive cells both in HepG2 and HepG2-8960-R (Figure 3b). We next examined DNA ladder formation, a hallmark of apoptosis. Although 5 days after AR, many dead cells were observed in the cell culture (Figure 1e), DNA ladder formation was not observed in both HepG2 and HepG2-8960-R at any time examined (Supplementary Figure S1A). Radiation-induced DNA ladder formation was not detectable in SAS and SAS-R (Supplementary Figure S1B). We further examined the expression of cleaved caspase 3 after irradiation. After AR, significant increase in cleaved caspase 3 was not detectable by western blotting from 0 to 7 days after AR in all cell lines examined (data not shown). Radiosensitivity under the inhibition of apoptosis by Z-VAD-FMK was evaluated. The inhibition of apoptosis sensitized both HepG2 and HepG2-8960-R to X-rays slightly at lower doses and significantly at 10 Gy (Supplementary Figures S2A and B). However, the inhibition of apoptosis did not affect surviving fractions of SAS and SAS-R (Supplementary Figures S2C and D). These results indicated that contribution of apoptosis to cellular radiosensitivity is lower than previously considered.
Figure 3
Frequencies of annexin V-positive cells induced by 10 Gy of a single dose of X-rays or fractionated X-rays. Basal levels of annexin V-positive cells in radioresistant HepG2-8960-R were higher than those in parental HepG2. (a) Annexin V-positive cells in HepG2 and HepG2-8960-R increased after acute exposure, however, induction level of annexin V-positive cells in HepG2 was higher than that in HepG2-8960-R. (b) Statistically significant induction of apoptosis was not observed both in HepG2 and HepG2-8960-R after exposure to fractionated 2 Gy of X-rays. Mean±S.D. of three independent experiments. *P<0.05 compared with control
Autophagy induced by X-ray exposure
We analyzed immunocytochemically positive cells for LC-3, a marker of autophagosomes. AR induced cells whose cytoplasm was filled with autophagosomes both in HepG2 and HepG2-8960-R (Figure 4). We defined these characteristic cells as ‘hyperinduced autophagic cells' (Figures 4b and c). The frequency of hyperinduced autophagic cells in HepG2-8960-R (24.0±5.2%) was significantly higher than that in HepG2 (1.5±0.7%). Within 24 h after AR of 10 Gy, hyperinduced autophagic cells did not increase in both HepG2 and HepG2-8960-R (Supplementary Figure S3). Electron microscopic observation also confirmed that autophagic cell death was induced both in HepG2 and HepG2-8960-R by AR (Figures 4e–h). The frequency of hyperinduced autophagic cells in HepG2 gradually increased from day 3 and reached 78.2±6.1% at day 7 after AR (Figure 5a). On the contrary, marked induction of hyperinduced autophagic cells was not observed in HepG2-8960-R and the frequency was 40.9±8.6% at day 7. Exposure to 5 × 2 Gy of FR remarkably induced hyperinduced autophagic cells in HepG2 (45.9±6.9%) but not in HepG2-8960-R (24.2±1.8% Figure 5b). We next examined the conversion of LC3-I to LC3-II, which is an indicator of autophagic activity and the amount of LC3-II correlates well with the number of autophagosomes.[22] At day 5 after AR, LC3-II level increased in both HepG2 and HepG2-8960-R, and the induction level was higher in HepG2 than in HepG2-8960-R (Figure 5c). We further examined the expression level of p62, which accumulates when autophagy is inhibited and decreases when autophagy is induced.[23] Without irradiation the expression level of p62 in HepG2 was higher than that in HepG2-8960-R (Figure 5d). The expression of p62 in HepG2 remained reduced from day 3 to 7 after AR and that in HepG2-8960-R reduced at day 3 but returned to the basal level by day 7.
Figure 4
(a–d) Representative figures of hyperinduced autophagic cells by a single dose of 10-Gy X-rays in parental HepG2 and radioresistant HepG2-8960-R cells. Autophagosomes were immunocytochemically visualized by anti-LC-3 antibody and cells filled with autophagosomes were counted as hyperinduced autophagic cells (arrows). (e–h) Electron microscopic analysis of HepG2 and HepG2-8960-R. (a) Hyperinduced autophagic cells were seldom observed in HepG2 cells without irradiation. (b) At day 7 after exposure to 10 Gy of X-rays, the level of hyperinduced autophagic HepG2 cells was 78.2±6.1%. (c) HepG2-8960-R cells 2 days after the last maintenance irradiation (2 Gy per day). (d) At day 7 after exposure to 10 Gy of X-rays, significant induction of hyperinduced autophagic cells was not observed in HepG2-8960-R. (e) HepG2 cells without X-rays. (f) At day 5 after exposure to 10 Gy of X-rays, HepG2 cells were filled with autophagosomes (arrow head). (g) HepG2-8960-R cell 2 days after the last maintenance irradiation (2 Gy per day). (h) HepG2-8960-R cell filled with autophagosomes at day 5 after exposure to 10 Gy of X-rays
Figure 5
(a) Hyperinduced autophagic cells by 10 Gy of X-rays in parental HepG2 and radioresistant HepG2-8960-R cells. The induction level of hyperinduced autophagic cells in HepG2-8960-R was lower than that in HepG2. (b) Hyperinduced autophagic cells by fractionated 2 Gy of X-rays. Hyperinduced autophagic cells of HepG2 were gradually increased along with the dose. No increase in hyperinduced autophagic cells was observed in HepG2-8960-R after exposure to total 10 Gy of X-rays. Mean±S.D. of three independent experiments. **P<0.01, *P<0.05 compared with control. (c) Western blot analysis of LC3 protein after X-irradiation. At day 5 after exposure to 10 Gy of X-rays, the increase in LC3-II, a hallmark of the induction of autophagy, was observed in both parental HepG2 and radioresistant HepG2-8960-R, and the amount of LC3-II in HepG2 was higher than that in HepG2-8960-R. (d) Western blot analysis of p62 protein after X-irradiation. At day 5 after exposure to 10 Gy of X-rays, the reduction of p62 protein, a hallmark of the induction of autophagy, was observed in both parental HepG2 and radioresistant HepG2-8960-R, and the amount of p62 protein in HepG2 was reduced much more than that in HepG2-8960-R
Radiosensitization of CRR cells via induction of autophagy
Radiosensitivity after facilitation of autophagy by RPM was evaluated. Chronic exposure to radiation reduces plating efficiency on which reproducibility of clonogenic assay depends. Therefore, in this study the modified high-density survival (HDS) assay instead of clonogenic assay was used to determine cellular radiosensitivity. HepG2-8960-R and all other CRR cell lines examined were significantly radioresistant compared with their corresponding parental cell lines (Figure 6a, Supplementary Figure S4). Radiosensitivity of HepG2-8960-R with RPM treatment became almost the same as that of HepG2 (Figure 6b). RPM also sensitized both HepG2-R and SAS-R (Supplementary Figures S4B and D) and its radiosensitizing effect tended to be higher at higher doses. Radiosensitivity of HepG2 with or without RPM was not significantly different (Supplementary Figure S5A). The inhibition of autophagy by 3-methyladenine (3-MA) did not radiosensitize HepG2-8960-R (Supplementary Figure S5D), but made HepG2 radioresistant to the level of HepG2-8960-R and even more resistant than HepG2-R (Figure 6C and Supplementary Figure S6B). Radioresistance was also induced in SAS by 3-MA (Supplementary Figure S6D). However, these effects were not observed in both HepG2-R and SAS-R (Supplementary Figures S6B and D).
Figure 6
(a) HepG2-8960-R was significantly more radioresistant than HepG2 at all doses examined. (b) The effect of RPM on radiosensitivity of HepG2 and HepG2-8960-R. RPM canceled radioresistance of HepG2-8960-R to the levels of HepG2. (c) The effect of 3-MA on radiosensitivity of HepG2 and HepG2-8960-R. HepG2 cells acquired the radioresistant phenotype by the administration of 3-MA. Mean±S.D. of three independent experiments was calculated. *P<0.05, **P<0.01
Autophagy induced by FR
RPM at the concentration of 10 ng/ml for 5 days was not toxic to HepG2 (Figure 7a), but significantly suppressed cell growth of HepG2-8960-R at day 5 (Figure 7b). FR alone suppressed cell growth of HepG2 (Supplementary Figure S7A), but additional radiosensitizing effect of RPM was not detected (Figure 7c). On the other hand, cell growth of HepG2-8960-R was drastically suppressed by the administration of FR and RPM (Figure 7d) and this effect was reinforced by FR (Supplementary Figure S7D).
Figure 7
(a–d) Combined effect of FR of 2 Gy of X-rays (FR) and RPM on cell growth. (a) RPM (10 ng/ml) did not affect cell growth of HepG2. (b) RPM significantly suppressed cell growth of HepG2-8960-R without radiation. (c) Until cumulative dose of 10 Gy, RPM did not affect cell growth of HepG2. (d) Cell growth of HepG2-8960-R was significantly suppressed by the administration of RPM with cumulative 10 Gy of X-rays. (e–h) Combined effect of fractionated 2 Gy of X-rays and administration of 3-MA on cell growth. (e) Cell growth of HepG2 was suppressed by the administration of 3-MA, but no significance was detected at any point examined. (f) Administration of 3-MA had no effect on cell growth of HepG2-8960-R cells. (g) Cell growth of HepG2 with fractionated 2 Gy of X-rays was not significantly different between with and without 3-MA. (h) Cell growth of HepG2-8960-R with fractionated 2 Gy of X-rays was not different between with and without 3-MA. Mean±S.D. of three independent experiments were calculated. *P<0.01
Cell growth of HepG2 was suppressed by 3-MA (Figure 7e). The effect of 3-MA on the cell growth was not obvious in HepG2-8960-R (Figure 7f). Radiosensitizing effect of 3-MA on FR was not observed both in HepG2 (Figure 7g, Supplementary Figure S7E) and in HepG2-8960-R (Figure 7h, Supplementary Figure S7F).Radiosensitizing effect of RPM was also confirmed in HepG2-R and SAS-R cells but not in SAS cells, indicating that the CRR phenotype is reversed by RPM (Supplementary Figures S8B, D and F). On the other hand, administration of 3-MA conferred radioresistance on SAS against FR (Supplementary Figure S8D).We next examined whether administration of RPM or 3-MA induces apoptosis, mitotic catastrophe or hyperinduced autophagic cells. At day 5 after irradiation, the frequency of annexin V-positive cells was not significantly different between with or without RPM or 3-MA (Supplementary Figure S9A). The induction frequency of mitotic catastrophe was not different between HepG2 and HepG2-8960-R irrespective of RPM or 3-MA treatments (Supplementary Figure S9B). Although RPM increased the frequency of hyperinduced autophagic cells in HepG2-8960-R 7 days after AR, unexpectedly did not in HepG2. Administration of 3-MA suppressed X-ray-induced hyperinduced autophagic cells in HepG2 (Supplementary Figure 9C).
Beclin-1 knockdown and radiosensitivity
We further examined whether inhibition of autophagy by knockdown of Beclin-1 induces radioresistance or not. We used psiRNA-hBeclin-1 for knockdown and siRNA-Luc for control of transfection. HepG2 gradually died out during selection for psiRNA-hBeclin-1 transfectant for three independent experiments. Without irradiation, autophagosomes were not observed both in siRNA-Luc SAS and psiRNA-hBeclin-1 SAS (Figure 8a). Five days after exposure to 10-GyAR, increases of the nuclear size and autophagosomes were observed in siRNA-Luc SAS. On the other hand, notable increase in autophagosomes was not observed in psiRNA-hBeclin-1 SAS. These results indicated that induction of autophagy by AR is suppressed in psiRNA-hBeclin-1 SAS. Compared with siRNA-Luc SAS, induction of hyperinduced autophagic cells 5 days after exposure to AR was significantly suppressed in psiRNA-hBeclin-1 SAS (Figure 8b). We next examined whether inhibition of autophagy induces cellular radioresistance or not. Compared with siRNA-Luc SAS radioresistance of psiRNA-hBeclin-1 SAS was observed (Figure 8c). Growth rate of psiRNA-hBeclin-1 SAS was slightly slower than that of siRNA-Luc SAS (Figure 8d). Compared with un-irradiated cells, FR of 5 × 2-Gy suppressed cell growth of both siRNA-Luc SAS and psiRNA-hBeclin-1 SAS but the suppression level was not significantly different. These results indicated that autophagy is a determinant factor of cellular radiosensitivity at least after AR of X-rays.
Figure 8
(a) Representative figures of autophagic cells induced by a single dose of 10-Gy X-rays in siRNA-Luc SAS and psiRNA-hBeclin-1 SAS cells. Autophagosomes were immunocytochemically visualized by anti-LC-3 antibody. (a-1) siRNA-Luc SAS cells without irradiation. (a-2) siRNA-Luc SAS cells 5 days after exposure to 10 Gy. In almost all cells the number of autophagosomes were increased. Some cells entered into hyperinduced autophagic cells (arrows). (a-3) siRNA-Luc SAS cells 5 days after exposure to 10 Gy of X-rays. High magnification. (a-4) psiRNA-hBeclin-1 SAS cells without irradiation. These cells express GFP as a marker for transfection. Therefore faint fluorescence was observed in nuclei. (a-5) psiRNA-hBeclin-1 SAS cells 5 days after exposure to 10 Gy of X-rays. Although autophagosomes were observed in cytoplasm, the number was apparently lower than that of siRNA-Luc SAS cells, indicating that induction of autophagy is suppressed by Beclin-1 knockdown. (a-6) psiRNA-hBeclin-1 SAS cells 5 days after exposure to 10 Gy of X-rays. High magnification. (b) Hyperinduced autophagic cells 5 days after exposure to 10 Gy of X-rays in siRNA-Luc SAS and psiRNA-hBeclin-1 SAS cells. (c) Radiation sensitivity of siRNA-Luc SAS and psiRNA-hBeclin-1 SAS. (d) Cell growth of siRNA-Luc SAS and psiRNA-hBeclin-1 SAS without radiation or 5 × 2 Gy of X-rays. Mean±S.D. of three independent experiments. *P<0.05
Discussion
Although radiotherapy is a well-established modality for various cancers, appearance of radioresistant cells is one of the major concerns. In order to understand and conquer radioresistant tumors, we have established CRR cell lines.[20, 21] Profile of radiation-induced cell death under a microscope could be divided into two major types: cell death with apoptotic bodies and that lacking apoptotic bodies. We speculated that the latter was autophagic cell death. This study revealed that apoptotic changes were observed but the induction level of apoptosis was very low both in parental and CRR cells. Moreover, the inhibition of apoptosis by a caspase inhibitor, Z-VAD-FMK, did not always radiosensitize both CRR and their parental cells. These suggest that contribution of apoptosis to cellular radiosensitivity is not remarkable. One of the hallmarks of cancer cells is thought to evade apoptosis.[24, 25] However, apoptosis has little or no effect on clonogenic survival after treatment with anticancer drugs or radiation in several tumor cell lines.[2] Recently, mounting evidences suggest that cancer cells can commit to death by various non-apoptotic pathways such as autophagy,[26] mitotic catastrophe and accelerated senescence.[4] In this study, maximum level of mitotic catastrophe within a week after AR was approximately 10% of HepG2 cells. This observation prompted us to examine the contribution of autophagic cell death to cellular radiosensitivity.Autophagic cell death known as type II programmed cell death is independent of phagocytes and differs from apoptosis by the presence of autophagosomes, autolysosomes and an intact nucleus in the cell.[27] In this study, electron microscopic study revealed that radiation exposure-induced characteristic morphology to autophagic cell death. Recently, autophagy is widely investigated in the field of radiation oncology.[28] However, the role of autophagy for cellular radiosensitivity remains to be elucidated. In this study, induction of autophagy by radiation was time dependent, which is consistent with Paglin et al.[15] But they reported that the induction of autophagy protects cells from radiation. In this study, microscopic observation of LC3 immunocytochemistry revealed cells characterized by their cytoplasm filled with autophagosomes other than cells with a few autophagosomes. As the frequency of this distinctive type of cells increased after AR, we coined them ‘hyperinduced autophagic cells'. The frequency of hyperinduced autophagic cells in parental cells increased after AR and was significantly higher than in CRR cells 7 days after AR. Western blot analysis of LC3-II revealed that the number of autophagosomes both at the basal level and the induced level after AR were lower in CRR cells than in parental cells. Western blotting of p62 revealed that the autophagy function at the basal level was higher in CRR cells than in parental cells. Both the number and the function of autophagosomes were increased by AR in parental cells while not obvious in CRR cells. These suggest that hyperinduced autophagy is associated with radiation-induced cell death albeit basal level of autophagy may contribute to the protection of cells.RPM induces autophagy and combination with radiation facilitates the development of autophagy in human mammary carcinomaMCF-7 cells accompanied with reduction of cell survival.[29] In this study, radiosensitizing effect of RPM on parental cells was not observed, presumably because we used RPM at the concentration of 1/10 of the usually reported to avoid its toxic effects. We confirmed that this dose was enough to induce autophagy after exposure to 10 Gy in CRR cells. The HDS assay with RPM showed that lower dose of RPM than usual was enough to reverse radioresistance of CRR cells to the levels of their corresponding parental cells. Therefore, treatments with low dose RPM would be useful to sensitize radioresistant tumors. Inhibition of autophagy by 3-MA did not change radiosensitivity of CRR cells, but increased radioresistance in parental cells to the levels of corresponding CRR cells after exposure to AR. Inhibition of autophagy by knockdown of Beclin-1 in SAS cells also induced radioresistance against AR. Lin et al.[30] reported that the inhibition of autophagy promotes resistance of papillary thyroid cancer (PTC) to radiation and the activation of autophagy may be a useful adjunct treatment for patients with PTC that is refractory to conventional therapy. In this study, 3-MA did not make parental cells radioresistant to FR. The frequency of hyperinduced autophagic cells in HepG2 was 80% at day 7 after exposure to 10 Gy of AR whereas 45% after exposure to 5 × 2 Gy of FR. Compared with AR the lower levels of induced autophagy by FR may partly contribute to the reason why the inhibition of autophagy either by 3-MA or Beclin-1 knockdown had lower impact on the cellular radioresistance of parental cells. In this study, we failed in obtaining Beclin-1 knockdown HepG2. This suggests that the basal level of autophagy is inevitable for cell survival though the level required is cell line dependent. Basal level of autophagy is necessary for cell survival against cellular stresses.[31] In this study, the function of autophagy at the basal level for cell protection is suggested to be higher in CRR cells than in parental cells. Radioresistance can be acquired through moderate dose of FR for 1 month.[20] These suggest that factor(s) to determine whether autophagy is involved in cell survival or cell death is different between CRR cells and parental cells.This study also strongly suggested that the activation of autophagy may overcome tumor radioresistance. Those are consistent with reports that the activation of autophagy may yield significant benefit for cancerpatients undergoing radiotherapy.[32, 33, 34] Radioresistant tumors could be surmountable by radiotherapy in combination with autophagy inducers such as RPM and RAD001 (everolimus).[35]Radiation-induced cell death in HepG2 began to increase 4 days after AR with the increase in mitotic catastrophe. Mitotic catastrophe is a well-established response to ionizing radiation.[36] Mitotic catastrophe occurs either during or shortly after a dysregulated/failed mitosis and is thought to be the process to cell death.[37] In this study, mitotic figures started increasing 3 days after AR, suggesting that cells failed to progress mitosis go into cell death. We presented here that about 80% of HepG2 cells after exposure to AR underwent autophagic cell death. Roughly 1/3 of cells in mitotic catastrophe were filled with autophagosomes, suggesting that these cells would die through autophagic cell death. Therefore, we think the majority of radiation-induced cell death is autophagic cell death.This study revealed that induction of autophagy sensitized CRR cells both to AR and FR. Therefore, we conclude that the modality to induce autophagy can be one of the effective approaches to conquer radioresistant tumors.[38] We started experiments on xenografted tumors of CRR cells into nude mice to evaluate whether the inhibition of mTOR pathway is effective to eradicate radioresistant tumors or not.
Materials and Methods
Cell culture and chemicals
HepG2 cells derived from humanliver cancer and SAS cells from humanoral cancer were obtained from the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University. We established CRR cell lines, HepG2-8960-R and HepG2-R from HepG2, and SAS-R from SAS independently. For the maintenance of the CRR phenotype, FR of X-rays at 2 Gy was performed every 24 h. All cells used in this study were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Nacalai Tesque Inc., Kyoto, Japan) supplemented with 5% fetal bovine serum (Gibco Invitrogen Corp., Carlsbad, CA, USA) in a humidified atmosphere at 37 °C with 5% CO2 in an air. In this study, acute exposure experiments were performed with cells in the exponentially growing phase and 24 h after the last maintenance irradiation.As an inhibitor of apoptosis, Z-VAD-FMK (20 μM) was used (Promega KK, Tokyo, Japan). For the induction of autophagy, RPM (Nacalai Tesque Inc.) dissolved in ethanol (1 mg/ml) was used at the final concentration of 10 ng/ml.[39] As an inhibitor of autophagy, 3-MA (Sigma-Aldrich Inc., St. Louis, MO, USA) was used at the concentration of 1 mM by directly dissolved in culture medium before use.[40] These agents were administered in cell culture 24 h before experiments.
Irradiation
X-ray irradiation was performed in a 150-KVp X-ray generator (Model MBR-1520R, Hitachi, Tokyo, Japan) with a total filtration of 0.5 mm aluminum plus 0.1 mm copper filter at a dose rate of 1.0 Gy/min. In this study, we performed two different modes of irradiation, FR and AR. Exposure schedule of FR consisted of 2 Gy of X-rays every 24 h up to 5 days (total 10 Gy) and AR consisted of exposure to a single dose of 10-Gy X-rays.
Detection of apoptotic cells
To determine the percentage of cells undergoing apoptosis, FITCannexin V/Dead Cell Apoptosis Kit (Molecular Probes, Eugene, OR, USA) was used according to the manufacture's protocol. Briefly, after exposure to X-rays, cells were washed with PBS and stained with annexin V. Immediately after staining, annexin V-positive cells were scored under a fluorescent microscope.
Detection of mitotic catastrophe
After exposure to X-rays, cells were fixed with methyl alcohol and stained with giemsa solution. Cells with more than two nucleus and micronuclei were considered as mitotic catastrophe.
Immunocytochemical detection of autophagy
Cells were seeded on a cover slip 48 h before radiation exposure experiments. At an appropriate time after irradiation, cells were rinsed twice with phosphate-buffered saline (PBS) and then fixed with 4% paraformaldehyde in PBS for 10 min at room temperature (RT). Cells were washed twice more with PBS and immersed in 100 μg/ml of Digitonin (Wako Pure Chemical Industries, Ltd., Osaka, Japan) in PBS for 15 min at RT. After two more washings with PBS, anti-LC3 primary antibody (Medical and Biological Laboratories Co., Ltd., Nagoya, Japan) was applied. After 1-h incubation at RT, cells were washed three times with PBS (5 min each). Cells were then incubated with fluorescein-conjugated second antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) in PBS for 30 min at RT. Then, cells were washed three times with PBS (5 min each) and Vectorshield (Vector Laboratories, Inc., Burlingame, CA, USA) was mounted onto the cover slips. Autophagosomes were visualized in a fluorescence microscope (BZ-8000, Keyence, Osaka, Japan).
The HDS assay
Cell survival was determined by the modified HDS assay.[21] Briefly, exponentially growing cells were seeded in 25 cm2 flasks at 1 × 105 per flask for parental cells and 2.5 × 105 per flask for CRR cells. After 24-h incubation, cells were exposed to various doses of X-rays and incubated for another 72 h. Subsequently, 1/10 of the cells of each flask were seeded into another 25 cm2 flask and incubated for further 72 h. Then total number of cells in each flask was counted by Trypan blue dye exclusion test and cell survival was plotted.
Western blot analysis
To prepare whole cell lysate, cells were washed twice with ice-cold PBS and resuspended in a lysis buffer containing 25 mM sodium phosphate (pH7.4), 500 mM NaCl, 1 mM ethylenediaminetetraacetic acid (pH 8.0), 0.5% Triton-X100, 0.1% glycerol, 5 mM MgCl2, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and Protease Inhibitor Cocktail (Nacalai Tesque Inc.). Cells were centrifuged for 20 min at 4 °C and clarified supernatants were stored at −80 °C until use. The whole cell lysate (20 μg) was electrophoresed in sodium dodecyl sulfatepolyacrylamide gel and was electroblotted onto a polyvinylidene fluoride membrane. After blocking with 5% skim milk for overnight at 4 °C, the membrane was incubated for overnight with primary antibodies at 4 °C and then incubated with horseradish peroxidase-conjugated secondary antibodies (Nichirei Corporation, Tokyo, Japan). Anti-cleaved caspase-3 antibody and anti-LC3 antibody were purchased from Cell Signaling Technology Japan, KK (Tokyo, Japan) and anti-p62/SQSTM1 antibody from MBL Co., Ltd., Nagaya, Japan). Bands were visualized with Chemi-Lumi One L western blotting substrate (Nacalai Tesque Inc.).
DNA fragmentation assay
After harvesting cells including detached cells were washed twice with ice-cold PBS and genomic DNA was extracted using DNeasy Blood and Tissue Kit (Qiagen K K, Tokyo, Japan).
Cell survival after exposure to fractionated 2 Gy of X-rays
Cells (1 × 105) were seeded into a 25-cm2 flask (Nalge Nunc International, Rochester, NY, USA) 48 h before the first experimental irradiation, and 24 h later RPM or 3-MA was administered. These cells were daily exposed to 2 Gy of X-rays for 5 consecutive days without medium exchange. At the appropriate time point during this experiment, total number of cells was scored and relative value of control was calculated.
Electron microscopy
HepG2 cells grown in 60-mm culture dishes were washed twice with PBS. Cells were fixed in 100 mM phosphate buffer, pH 7.4, containing 2.5% glutaraldehyde for 30 min at 4 °C. The cells were rinsed twice with ice-cold PBS, post-fixed in OsO4, dehydrated in graded acetone and embedded in epoxy resin. Ultrathin sections were prepared with Ultra-microtome (Leica Microsystems Japan, Tokyo, Japan), mounted in copper grids, and counterstained with uranyl acetate and lead citrate. Photographs were obtained using transmission electron microscope (Hitachi High-Technologies Corporation, Tokyo, Japan).
Inhibition of autophagy by Beclin-1 knockdown
In order to inhibit autophagy, a psiRNA-hBeclin-1 Kit was used according to the manufacture's protocol (InvivoGen, San Diego, CA, USA). Briefly, cells were transfected with expression vector using HilyMax (Dojindo, Kumamoto, Japan). These cells were cultured in RPMI medium containing 5% fetal bovine serum and Zeocin (100 μg/ml, InvivoGen) for 2 weeks. The viable cell preparation was used for experiments.
Statistical analysis
At each data point, the mean and S.D. were calculated and statistically analyzed using Student's t-test.
Authors: Chi-Iou Lin; Edward E Whang; David B Donner; Jinyan Du; Jochen Lorch; Frank He; Xiaofeng Jiang; Brendan D Price; Francis D Moore; Daniel T Ruan Journal: Mol Cancer Res Date: 2010-08-24 Impact factor: 5.852
Authors: W Bursch; A Ellinger; H Kienzl; L Török; S Pandey; M Sikorska; R Walker; R S Hermann Journal: Carcinogenesis Date: 1996-08 Impact factor: 4.944
Authors: Daniel J Klionsky; Fabio C Abdalla; Hagai Abeliovich; Robert T Abraham; Abraham Acevedo-Arozena; Khosrow Adeli; Lotta Agholme; Maria Agnello; Patrizia Agostinis; Julio A Aguirre-Ghiso; Hyung Jun Ahn; Ouardia Ait-Mohamed; Slimane Ait-Si-Ali; Takahiko Akematsu; Shizuo Akira; Hesham M Al-Younes; Munir A Al-Zeer; Matthew L Albert; Roger L Albin; Javier Alegre-Abarrategui; Maria Francesca Aleo; Mehrdad Alirezaei; Alexandru Almasan; Maylin Almonte-Becerril; Atsuo Amano; Ravi Amaravadi; Shoba Amarnath; Amal O Amer; Nathalie Andrieu-Abadie; Vellareddy Anantharam; David K Ann; Shailendra Anoopkumar-Dukie; Hiroshi Aoki; Nadezda Apostolova; Giuseppe Arancia; John P Aris; Katsuhiko Asanuma; Nana Y O Asare; Hisashi Ashida; Valerie Askanas; David S Askew; Patrick Auberger; Misuzu Baba; Steven K Backues; Eric H Baehrecke; Ben A Bahr; Xue-Yuan Bai; Yannick Bailly; Robert Baiocchi; Giulia Baldini; Walter Balduini; Andrea Ballabio; Bruce A Bamber; Edward T W Bampton; Gábor Bánhegyi; Clinton R Bartholomew; Diane C Bassham; Robert C Bast; Henri Batoko; Boon-Huat Bay; Isabelle Beau; Daniel M Béchet; Thomas J Begley; Christian Behl; Christian Behrends; Soumeya Bekri; Bryan Bellaire; Linda J Bendall; Luca Benetti; Laura Berliocchi; Henri Bernardi; Francesca Bernassola; Sébastien Besteiro; Ingrid Bhatia-Kissova; Xiaoning Bi; Martine Biard-Piechaczyk; Janice S Blum; Lawrence H Boise; Paolo Bonaldo; David L Boone; Beat C Bornhauser; Karina R Bortoluci; Ioannis Bossis; Frédéric Bost; Jean-Pierre Bourquin; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan R Brady; Claudio Brancolini; Andreas Brech; Jay E Brenman; Ana Brennand; Emery H Bresnick; Patrick Brest; Dave Bridges; Molly L Bristol; Paul S Brookes; Eric J Brown; John H Brumell; Nicola Brunetti-Pierri; Ulf T Brunk; Dennis E Bulman; Scott J Bultman; Geert Bultynck; Lena F Burbulla; Wilfried Bursch; Jonathan P Butchar; Wanda Buzgariu; Sergio P Bydlowski; Ken Cadwell; Monika Cahová; Dongsheng Cai; Jiyang Cai; Qian Cai; Bruno Calabretta; Javier Calvo-Garrido; Nadine Camougrand; Michelangelo Campanella; Jenny Campos-Salinas; Eleonora Candi; Lizhi Cao; Allan B Caplan; Simon R Carding; Sandra M Cardoso; Jennifer S Carew; Cathleen R Carlin; Virginie Carmignac; Leticia A M Carneiro; Serena Carra; Rosario A Caruso; Giorgio Casari; Caty Casas; Roberta Castino; Eduardo Cebollero; Francesco Cecconi; Jean Celli; Hassan Chaachouay; Han-Jung Chae; Chee-Yin Chai; David C Chan; Edmond Y Chan; Raymond Chuen-Chung Chang; Chi-Ming Che; Ching-Chow Chen; Guang-Chao Chen; Guo-Qiang Chen; Min Chen; Quan Chen; Steve S-L Chen; WenLi Chen; Xi Chen; Xiangmei Chen; Xiequn Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Zhixiang Chen; Alan Cheng; Christopher H K Cheng; Yan Cheng; Heesun Cheong; Jae-Ho Cheong; Sara Cherry; Russ Chess-Williams; Zelda H Cheung; Eric Chevet; Hui-Ling Chiang; Roberto Chiarelli; Tomoki Chiba; Lih-Shen Chin; Shih-Hwa Chiou; Francis V Chisari; Chi Hin Cho; Dong-Hyung Cho; Augustine M K Choi; DooSeok Choi; Kyeong Sook Choi; Mary E Choi; Salem Chouaib; Divaker Choubey; Vinay Choubey; Charleen T Chu; Tsung-Hsien Chuang; Sheau-Huei Chueh; Taehoon Chun; Yong-Joon Chwae; Mee-Len Chye; Roberto Ciarcia; Maria R Ciriolo; Michael J Clague; Robert S B Clark; Peter G H Clarke; Robert Clarke; Patrice Codogno; Hilary A Coller; María I Colombo; Sergio Comincini; Maria Condello; Fabrizio Condorelli; Mark R Cookson; Graham H Coombs; Isabelle Coppens; Ramon Corbalan; Pascale Cossart; Paola Costelli; Safia Costes; Ana Coto-Montes; Eduardo Couve; Fraser P Coxon; James M Cregg; José L Crespo; Marianne J Cronjé; Ana Maria Cuervo; Joseph J Cullen; Mark J Czaja; Marcello D'Amelio; Arlette Darfeuille-Michaud; Lester M Davids; Faith E Davies; Massimo De Felici; John F de Groot; Cornelis A M de Haan; Luisa De Martino; Angelo De Milito; Vincenzo De Tata; Jayanta Debnath; Alexei Degterev; Benjamin Dehay; Lea M D Delbridge; Francesca Demarchi; Yi Zhen Deng; Jörn Dengjel; Paul Dent; Donna Denton; Vojo Deretic; Shyamal D Desai; Rodney J Devenish; Mario Di Gioacchino; Gilbert Di Paolo; Chiara Di Pietro; Guillermo Díaz-Araya; Inés Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Ivan Dikic; Savithramma P Dinesh-Kumar; Wen-Xing Ding; Clark W Distelhorst; Abhinav Diwan; Mojgan Djavaheri-Mergny; Svetlana Dokudovskaya; Zheng Dong; Frank C Dorsey; Victor Dosenko; James J Dowling; Stephen Doxsey; Marlène Dreux; Mark E Drew; Qiuhong Duan; Michel A Duchosal; Karen Duff; Isabelle Dugail; Madeleine Durbeej; Michael Duszenko; Charles L Edelstein; Aimee L Edinger; Gustavo Egea; Ludwig Eichinger; N Tony Eissa; Suhendan Ekmekcioglu; Wafik S El-Deiry; Zvulun Elazar; Mohamed Elgendy; Lisa M Ellerby; Kai Er Eng; Anna-Mart Engelbrecht; Simone Engelender; Jekaterina Erenpreisa; Ricardo Escalante; Audrey Esclatine; Eeva-Liisa Eskelinen; Lucile Espert; Virginia Espina; Huizhou Fan; Jia Fan; Qi-Wen Fan; Zhen Fan; Shengyun Fang; Yongqi Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Jean-Claude Farré; Mathias Faure; Marcus Fechheimer; Carl G Feng; Jian Feng; Qili Feng; Youji Feng; László Fésüs; Ralph Feuer; Maria E Figueiredo-Pereira; Gian Maria Fimia; Diane C Fingar; Steven Finkbeiner; Toren Finkel; Kim D Finley; Filomena Fiorito; Edward A Fisher; Paul B Fisher; Marc Flajolet; Maria L Florez-McClure; Salvatore Florio; Edward A Fon; Francesco Fornai; Franco Fortunato; Rati Fotedar; Daniel H Fowler; Howard S Fox; Rodrigo Franco; Lisa B Frankel; Marc Fransen; José M Fuentes; Juan Fueyo; Jun Fujii; Kozo Fujisaki; Eriko Fujita; Mitsunori Fukuda; Ruth H Furukawa; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Brigitte Galliot; Vincent Galy; Subramaniam Ganesh; Barry Ganetzky; Ian G Ganley; Fen-Biao Gao; George F Gao; Jinming Gao; Lorena Garcia; Guillermo Garcia-Manero; Mikel Garcia-Marcos; Marjan Garmyn; Andrei L Gartel; Evelina Gatti; Mathias Gautel; Thomas R Gawriluk; Matthew E Gegg; Jiefei Geng; Marc Germain; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Pradipta Ghosh; Anna M Giammarioli; Alexandra N Giatromanolaki; Spencer B Gibson; Robert W Gilkerson; Michael L Ginger; Henry N Ginsberg; Jakub Golab; Michael S Goligorsky; Pierre Golstein; Candelaria Gomez-Manzano; Ebru Goncu; Céline Gongora; Claudio D Gonzalez; Ramon Gonzalez; Cristina González-Estévez; Rosa Ana González-Polo; Elena Gonzalez-Rey; Nikolai V Gorbunov; Sharon Gorski; Sandro Goruppi; Roberta A Gottlieb; Devrim Gozuacik; Giovanna Elvira Granato; Gary D Grant; Kim N Green; Aleš Gregorc; Frédéric Gros; Charles Grose; Thomas W Grunt; Philippe Gual; Jun-Lin Guan; Kun-Liang Guan; Sylvie M Guichard; Anna S Gukovskaya; Ilya Gukovsky; Jan Gunst; Asa B Gustafsson; Andrew J Halayko; Amber N Hale; Sandra K Halonen; Maho Hamasaki; Feng Han; Ting Han; Michael K Hancock; Malene Hansen; Hisashi Harada; Masaru Harada; Stefan E Hardt; J Wade Harper; Adrian L Harris; James Harris; Steven D Harris; Makoto Hashimoto; Jeffrey A Haspel; Shin-ichiro Hayashi; Lori A Hazelhurst; Congcong He; You-Wen He; Marie-Joseé Hébert; Kim A Heidenreich; Miep H Helfrich; Gudmundur V Helgason; Elizabeth P Henske; Brian Herman; Paul K Herman; Claudio Hetz; Sabine Hilfiker; Joseph A Hill; Lynne J Hocking; Paul Hofman; Thomas G Hofmann; Jörg Höhfeld; Tessa L Holyoake; Ming-Huang Hong; David A Hood; Gökhan S Hotamisligil; Ewout J Houwerzijl; Maria Høyer-Hansen; Bingren Hu; Chien-An A Hu; Hong-Ming Hu; Ya Hua; Canhua Huang; Ju Huang; Shengbing Huang; Wei-Pang Huang; Tobias B Huber; Won-Ki Huh; Tai-Ho Hung; Ted R Hupp; Gang Min Hur; James B Hurley; Sabah N A Hussain; Patrick J Hussey; Jung Jin Hwang; Seungmin Hwang; Atsuhiro Ichihara; Shirin Ilkhanizadeh; Ken Inoki; Takeshi Into; Valentina Iovane; Juan L Iovanna; Nancy Y Ip; Yoshitaka Isaka; Hiroyuki Ishida; Ciro Isidoro; Ken-ichi Isobe; Akiko Iwasaki; Marta Izquierdo; Yotaro Izumi; Panu M Jaakkola; Marja Jäättelä; George R Jackson; William T Jackson; Bassam Janji; Marina Jendrach; Ju-Hong Jeon; Eui-Bae Jeung; Hong Jiang; Hongchi Jiang; Jean X Jiang; Ming Jiang; Qing Jiang; Xuejun Jiang; Xuejun Jiang; Alberto Jiménez; Meiyan Jin; Shengkan Jin; Cheol O Joe; Terje Johansen; Daniel E Johnson; Gail V W Johnson; Nicola L Jones; Bertrand Joseph; Suresh K Joseph; Annie M Joubert; Gábor Juhász; Lucienne Juillerat-Jeanneret; Chang Hwa Jung; Yong-Keun Jung; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Motoni Kadowaki; Katarina Kagedal; Yoshiaki Kamada; Vitaliy O Kaminskyy; Harm H Kampinga; Hiromitsu Kanamori; Chanhee Kang; Khong Bee Kang; Kwang Il Kang; Rui Kang; Yoon-A Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Arthi Kanthasamy; Vassiliki Karantza; Gur P Kaushal; Susmita Kaushik; Yoshinori Kawazoe; Po-Yuan Ke; John H Kehrl; Ameeta Kelekar; Claus Kerkhoff; David H Kessel; Hany Khalil; Jan A K W Kiel; Amy A Kiger; Akio Kihara; Deok Ryong Kim; Do-Hyung Kim; Dong-Hou Kim; Eun-Kyoung Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; John K Kim; Peter K Kim; Seong Who Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Jason S King; Timothy J Kinsella; Vladimir Kirkin; Lorrie A Kirshenbaum; Katsuhiko Kitamoto; Kaio Kitazato; Ludger Klein; Walter T Klimecki; Jochen Klucken; Erwin Knecht; Ben C B Ko; Jan C Koch; Hiroshi Koga; Jae-Young Koh; Young Ho Koh; Masato Koike; Masaaki Komatsu; Eiki Kominami; Hee Jeong Kong; Wei-Jia Kong; Viktor I Korolchuk; Yaichiro Kotake; Michael I Koukourakis; Juan B Kouri Flores; Attila L Kovács; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Carole Kretz-Remy; Anna M Krichevsky; Guido Kroemer; Rejko Krüger; Oleg Krut; Nicholas T Ktistakis; Chia-Yi Kuan; Roza Kucharczyk; Ashok Kumar; Raj Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Tino Kurz; Ho Jeong Kwon; Albert R La Spada; Frank Lafont; Trond Lamark; Jacques Landry; Jon D Lane; Pierre Lapaquette; Jocelyn F Laporte; Lajos László; Sergio Lavandero; Josée N Lavoie; Robert Layfield; Pedro A Lazo; Weidong Le; Laurent Le Cam; Daniel J Ledbetter; Alvin J X Lee; Byung-Wan Lee; Gyun Min Lee; Jongdae Lee; Ju-Hyun Lee; Michael Lee; Myung-Shik Lee; Sug Hyung Lee; Christiaan Leeuwenburgh; Patrick Legembre; Renaud Legouis; Michael Lehmann; Huan-Yao Lei; Qun-Ying Lei; David A Leib; José Leiro; John J Lemasters; Antoinette Lemoine; Maciej S Lesniak; Dina Lev; Victor V Levenson; Beth Levine; Efrat Levy; Faqiang Li; Jun-Lin Li; Lian Li; Sheng Li; Weijie Li; Xue-Jun Li; Yan-bo Li; Yi-Ping Li; Chengyu Liang; Qiangrong Liang; Yung-Feng Liao; Pawel P Liberski; Andrew Lieberman; Hyunjung J Lim; Kah-Leong Lim; Kyu Lim; Chiou-Feng Lin; Fu-Cheng Lin; Jian Lin; Jiandie D Lin; Kui Lin; Wan-Wan Lin; Weei-Chin Lin; Yi-Ling Lin; Rafael Linden; Paul Lingor; Jennifer Lippincott-Schwartz; Michael P Lisanti; Paloma B Liton; Bo Liu; Chun-Feng Liu; Kaiyu Liu; Leyuan Liu; Qiong A Liu; Wei Liu; Young-Chau Liu; Yule Liu; Richard A Lockshin; Chun-Nam Lok; Sagar Lonial; Benjamin Loos; Gabriel Lopez-Berestein; Carlos López-Otín; Laura Lossi; Michael T Lotze; Peter Lőw; Binfeng Lu; Bingwei Lu; Bo Lu; Zhen Lu; Frédéric Luciano; Nicholas W Lukacs; Anders H Lund; Melinda A Lynch-Day; Yong Ma; Fernando Macian; Jeff P MacKeigan; Kay F Macleod; Frank Madeo; Luigi Maiuri; Maria Chiara Maiuri; Davide Malagoli; May Christine V Malicdan; Walter Malorni; Na Man; Eva-Maria Mandelkow; Stéphen Manon; Irena Manov; Kai Mao; Xiang Mao; Zixu Mao; Philippe Marambaud; Daniela Marazziti; Yves L Marcel; Katie Marchbank; Piero Marchetti; Stefan J Marciniak; Mateus Marcondes; Mohsen Mardi; Gabriella Marfe; Guillermo Mariño; Maria Markaki; Mark R Marten; Seamus J Martin; Camille Martinand-Mari; Wim Martinet; Marta Martinez-Vicente; Matilde Masini; Paola Matarrese; Saburo Matsuo; Raffaele Matteoni; Andreas Mayer; Nathalie M Mazure; David J McConkey; Melanie J McConnell; Catherine McDermott; Christine McDonald; Gerald M McInerney; Sharon L McKenna; BethAnn McLaughlin; Pamela J McLean; Christopher R McMaster; G Angus McQuibban; Alfred J Meijer; Miriam H Meisler; Alicia Meléndez; Thomas J Melia; Gerry Melino; Maria A Mena; Javier A Menendez; Rubem F S Menna-Barreto; Manoj B Menon; Fiona M Menzies; Carol A Mercer; Adalberto Merighi; Diane E Merry; Stefania Meschini; Christian G Meyer; Thomas F Meyer; Chao-Yu Miao; Jun-Ying Miao; Paul A M Michels; Carine Michiels; Dalibor Mijaljica; Ana Milojkovic; Saverio Minucci; Clelia Miracco; Cindy K Miranti; Ioannis Mitroulis; Keisuke Miyazawa; Noboru Mizushima; Baharia Mograbi; Simin Mohseni; Xavier Molero; Bertrand Mollereau; Faustino Mollinedo; Takashi Momoi; Iryna Monastyrska; Martha M Monick; Mervyn J Monteiro; Michael N Moore; Rodrigo Mora; Kevin Moreau; Paula I Moreira; Yuji Moriyasu; Jorge Moscat; Serge Mostowy; Jeremy C Mottram; Tomasz Motyl; Charbel E-H Moussa; Sylke Müller; Sylviane Muller; Karl Münger; Christian Münz; Leon O Murphy; Maureen E Murphy; Antonio Musarò; Indira Mysorekar; Eiichiro Nagata; Kazuhiro Nagata; Aimable Nahimana; Usha Nair; Toshiyuki Nakagawa; Kiichi Nakahira; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Naweed I Naqvi; Derek P Narendra; Masashi Narita; Miguel Navarro; Steffan T Nawrocki; Taras Y Nazarko; Andriy Nemchenko; Mihai G Netea; Thomas P Neufeld; Paul A Ney; Ioannis P Nezis; Huu Phuc Nguyen; Daotai Nie; Ichizo Nishino; Corey Nislow; Ralph A Nixon; Takeshi Noda; Angelika A Noegel; Anna Nogalska; Satoru Noguchi; Lucia Notterpek; Ivana Novak; Tomoyoshi Nozaki; Nobuyuki Nukina; Thorsten Nürnberger; Beat Nyfeler; Keisuke Obara; Terry D Oberley; Salvatore Oddo; Michinaga Ogawa; Toya Ohashi; Koji Okamoto; Nancy L Oleinick; F Javier Oliver; Laura J Olsen; Stefan Olsson; Onya Opota; Timothy F Osborne; Gary K Ostrander; Kinya Otsu; Jing-hsiung James Ou; Mireille Ouimet; Michael Overholtzer; Bulent Ozpolat; Paolo Paganetti; Ugo Pagnini; Nicolas Pallet; Glen E Palmer; Camilla Palumbo; Tianhong Pan; Theocharis Panaretakis; Udai Bhan Pandey; Zuzana Papackova; Issidora Papassideri; Irmgard Paris; Junsoo Park; Ohkmae K Park; Jan B Parys; Katherine R Parzych; Susann Patschan; Cam Patterson; Sophie Pattingre; John M Pawelek; Jianxin Peng; David H Perlmutter; Ida Perrotta; George Perry; Shazib Pervaiz; Matthias Peter; Godefridus J Peters; Morten Petersen; Goran Petrovski; James M Phang; Mauro Piacentini; Philippe Pierre; Valérie Pierrefite-Carle; Gérard Pierron; Ronit Pinkas-Kramarski; Antonio Piras; Natik Piri; Leonidas C Platanias; Stefanie Pöggeler; Marc Poirot; Angelo Poletti; Christian Poüs; Mercedes Pozuelo-Rubio; Mette Prætorius-Ibba; Anil Prasad; Mark Prescott; Muriel Priault; Nathalie Produit-Zengaffinen; Ann Progulske-Fox; Tassula Proikas-Cezanne; Serge Przedborski; Karin Przyklenk; Rosa Puertollano; Julien Puyal; Shu-Bing Qian; Liang Qin; Zheng-Hong Qin; Susan E Quaggin; Nina Raben; Hannah Rabinowich; Simon W Rabkin; Irfan Rahman; Abdelhaq Rami; Georg Ramm; Glenn Randall; Felix Randow; V Ashutosh Rao; Jeffrey C Rathmell; Brinda Ravikumar; Swapan K Ray; Bruce H Reed; John C Reed; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; John J Reiners; Russel J Reiter; Jun Ren; José L Revuelta; Christopher J Rhodes; Konstantinos Ritis; Elizete Rizzo; Jeffrey Robbins; Michel Roberge; Hernan Roca; Maria C Roccheri; Stephane Rocchi; H Peter Rodemann; Santiago Rodríguez de Córdoba; Bärbel Rohrer; Igor B Roninson; Kirill Rosen; Magdalena M Rost-Roszkowska; Mustapha Rouis; Kasper M A Rouschop; Francesca Rovetta; Brian P Rubin; David C Rubinsztein; Klaus Ruckdeschel; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Nelson Ruiz-Opazo; Rossella Russo; Tor Erik Rusten; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Junichi Sadoshima; Tapas Saha; Tatsuya Saitoh; Hiroshi Sakagami; Yasuyoshi Sakai; Ghasem Hoseini Salekdeh; Paolo Salomoni; Paul M Salvaterra; Guy Salvesen; Rosa Salvioli; Anthony M J Sanchez; José A Sánchez-Alcázar; Ricardo Sánchez-Prieto; Marco Sandri; Uma Sankar; Poonam Sansanwal; Laura Santambrogio; Shweta Saran; Sovan Sarkar; Minnie Sarwal; Chihiro Sasakawa; Ausra Sasnauskiene; Miklós Sass; Ken Sato; Miyuki Sato; Anthony H V Schapira; Michael Scharl; Hermann M Schätzl; Wiep Scheper; Stefano Schiaffino; Claudio Schneider; Marion E Schneider; Regine Schneider-Stock; Patricia V Schoenlein; Daniel F Schorderet; Christoph Schüller; Gary K Schwartz; Luca Scorrano; Linda Sealy; Per O Seglen; Juan Segura-Aguilar; Iban Seiliez; Oleksandr Seleverstov; Christian Sell; Jong Bok Seo; Duska Separovic; Vijayasaradhi Setaluri; Takao Setoguchi; Carmine Settembre; John J Shacka; Mala Shanmugam; Irving M Shapiro; Eitan Shaulian; Reuben J Shaw; James H Shelhamer; Han-Ming Shen; Wei-Chiang Shen; Zu-Hang Sheng; Yang Shi; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Takahiro Shintani; Orian S Shirihai; Gordon C Shore; Andriy A Sibirny; Stan B Sidhu; Beata Sikorska; Elaine C M Silva-Zacarin; Alison Simmons; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Anne Simonsen; David A Sinclair; Rajat Singh; Debasish Sinha; Frank A Sinicrope; Agnieszka Sirko; Parco M Siu; Efthimios Sivridis; Vojtech Skop; Vladimir P Skulachev; Ruth S Slack; Soraya S Smaili; Duncan R Smith; Maria S Soengas; Thierry Soldati; Xueqin Song; Anil K Sood; Tuck Wah Soong; Federica Sotgia; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Srinivasa M Srinivasula; Leonidas Stefanis; Joan S Steffan; Ruediger Stendel; Harald Stenmark; Anastasis Stephanou; Stephan T Stern; Cinthya Sternberg; Björn Stork; Peter Strålfors; Carlos S Subauste; Xinbing Sui; David Sulzer; Jiaren Sun; Shi-Yong Sun; Zhi-Jun Sun; Joseph J Y Sung; Kuninori Suzuki; Toshihiko Suzuki; Michele S Swanson; Charles Swanton; Sean T Sweeney; Lai-King Sy; Gyorgy Szabadkai; Ira Tabas; Heinrich Taegtmeyer; Marco Tafani; Krisztina Takács-Vellai; Yoshitaka Takano; Kaoru Takegawa; Genzou Takemura; Fumihiko Takeshita; Nicholas J Talbot; Kevin S W Tan; Keiji Tanaka; Kozo Tanaka; Daolin Tang; Dingzhong Tang; Isei Tanida; Bakhos A Tannous; Nektarios Tavernarakis; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Lance S Terada; Alexei Terman; Gianluca Tettamanti; Karin Thevissen; Craig B Thompson; Andrew Thorburn; Michael Thumm; FengFeng Tian; Yuan Tian; Glauco Tocchini-Valentini; Aviva M Tolkovsky; Yasuhiko Tomino; Lars Tönges; Sharon A Tooze; Cathy Tournier; John Tower; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Ting-Fen Tsai; Mario P Tschan; Takeshi Tsubata; Allan Tsung; Boris Turk; Lorianne S Turner; Suresh C Tyagi; Yasuo Uchiyama; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Vivek K Unni; Maria I Vaccaro; Enza Maria Valente; Greet Van den Berghe; Ida J van der Klei; Wouter van Doorn; Linda F van Dyk; Marjolein van Egmond; Leo A van Grunsven; Peter Vandenabeele; Wim P Vandenberghe; Ilse Vanhorebeek; Eva C Vaquero; Guillermo Velasco; Tibor Vellai; Jose Miguel Vicencio; Richard D Vierstra; Miquel Vila; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Olga V Voitsekhovskaja; Clarissa von Haefen; Marcela Votruba; Keiji Wada; Richard Wade-Martins; Cheryl L Walker; Craig M Walsh; Jochen Walter; Xiang-Bo Wan; Aimin Wang; Chenguang Wang; Dawei Wang; Fan Wang; Fen Wang; Guanghui Wang; Haichao Wang; Hong-Gang Wang; Horng-Dar Wang; Jin Wang; Ke Wang; Mei Wang; Richard C Wang; Xinglong Wang; Xuejun Wang; Ying-Jan Wang; Yipeng Wang; Zhen Wang; Zhigang Charles Wang; Zhinong Wang; Derick G Wansink; Diane M Ward; Hirotaka Watada; Sarah L Waters; Paul Webster; Lixin Wei; Conrad C Weihl; William A Weiss; Scott M Welford; Long-Ping Wen; Caroline A Whitehouse; J Lindsay Whitton; Alexander J Whitworth; Tom Wileman; John W Wiley; Simon Wilkinson; Dieter Willbold; Roger L Williams; Peter R Williamson; Bradly G Wouters; Chenghan Wu; Dao-Cheng Wu; William K K Wu; Andreas Wyttenbach; Ramnik J Xavier; Zhijun Xi; Pu Xia; Gengfu Xiao; Zhiping Xie; Zhonglin Xie; Da-zhi Xu; Jianzhen Xu; Liang Xu; Xiaolei Xu; Ai Yamamoto; Akitsugu Yamamoto; Shunhei Yamashina; Michiaki Yamashita; Xianghua Yan; Mitsuhiro Yanagida; Dun-Sheng Yang; Elizabeth Yang; Jin-Ming Yang; Shi Yu Yang; Wannian Yang; Wei Yuan Yang; Zhifen Yang; Meng-Chao Yao; Tso-Pang Yao; Behzad Yeganeh; Wei-Lien Yen; Jia-jing Yin; Xiao-Ming Yin; Ook-Joon Yoo; Gyesoon Yoon; Seung-Yong Yoon; Tomohiro Yorimitsu; Yuko Yoshikawa; Tamotsu Yoshimori; Kohki Yoshimoto; Ho Jin You; Richard J Youle; Anas Younes; Li Yu; Long Yu; Seong-Woon Yu; Wai Haung Yu; Zhi-Min Yuan; Zhenyu Yue; Cheol-Heui Yun; Michisuke Yuzaki; Olga Zabirnyk; Elaine Silva-Zacarin; David Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Zahra Zakeri; Herbert J Zeh; Scott O Zeitlin; Hong Zhang; Hui-Ling Zhang; Jianhua Zhang; Jing-Pu Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xu Dong Zhang; Mantong Zhao; Yi-Fang Zhao; Ying Zhao; Zhizhuang J Zhao; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Cong-Zhao Zhou; Changlian Zhu; Wei-Guo Zhu; Xiao-Feng Zhu; Xiongwei Zhu; Yuangang Zhu; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Jürgen Zschocke; Brian Zuckerbraun Journal: Autophagy Date: 2012-04 Impact factor: 16.016